Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

(177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy (Eβmax 0.497 MeV) and a shorter particle penetr...

Descripción completa

Detalles Bibliográficos
Autores principales: Parghane, Rahul V., Mitra, Arpit, Bannore, Trupti Upadhye, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034792/
https://www.ncbi.nlm.nih.gov/pubmed/33850492
http://dx.doi.org/10.4103/wjnm.WJNM_52_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034792/
https://www.ncbi.nlm.nih.gov/pubmed/33850492
http://dx.doi.org/10.4103/wjnm.WJNM_52_20

Ejemplares similares